Indeed, administration of IL-33 before tissue damage reduces inflammation via binding to the ST2 receptor of Tregs, while administration of IL-33 during the progression of GVHD induces cytotoxic T-cell activation (Reichenbach et al., 2015). This evidence concerns the gene IL33 and graft versus host disease.